Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 374

1.

Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study.

Bernasconi C, Pelkonen O, Andersson TB, Strickland J, Wilk-Zasadna I, Asturiol D, Cole T, Liska R, Worth A, Müller-Vieira U, Richert L, Chesne C, Coecke S.

Toxicol In Vitro. 2019 Oct;60:212-228. doi: 10.1016/j.tiv.2019.05.019. Epub 2019 May 31.

2.

Integration of epidemiological findings with mechanistic evidence in regulatory pesticide risk assessment: EFSA experiences.

Pelkonen O, Bennekou SH, Crivellente F, Terron A, Hernandez AF.

Arch Toxicol. 2019 Jun;93(6):1779-1788. doi: 10.1007/s00204-019-02467-w. Epub 2019 May 3.

PMID:
31053889
3.

Editorial.

Aschner M, Autrup HN, Cohen SM, Dekant W, Eisenbrand G, Galli CL, Gori GB, Kaminski NE, Klaassen CD, Klaunig JE, Levy L, Lotti M, Marquardt HW, Pelkonen O, Schrenk DF, Yamazaki H.

Regul Toxicol Pharmacol. 2019 Feb;101:A1-A2. doi: 10.1016/j.yrtph.2018.12.015. No abstract available.

PMID:
30642615
4.

Establishing a systematic framework to characterise in vitro methods for human hepatic metabolic clearance.

Gouliarmou V, Lostia AM, Coecke S, Bernasconi C, Bessems J, Dorne JL, Ferguson S, Testai E, Remy UG, Brian Houston J, Monshouwer M, Nong A, Pelkonen O, Morath S, Wetmore BA, Worth A, Zanelli U, Zorzoli MC, Whelan M.

Toxicol In Vitro. 2018 Dec;53:233-244. doi: 10.1016/j.tiv.2018.08.004. Epub 2018 Aug 9.

PMID:
30099088
5.

Obfuscating transparency?

Aschner M, Autrup H, Berry CL, Boobis AR, Cohen SM, Dekant W, Galli CL, Goodman JI, Gori GB, Greim HA, Kaminski NE, Klaassen CD, Klaunig JE, Lotti M, Marquardt HW, Moretto A, Pelkonen O, Sipes IG, Wallace KB, Yamazaki H.

Regul Toxicol Pharmacol. 2018 Aug;97:A1-A3. doi: 10.1016/j.yrtph.2018.07.004. Epub 2018 Jul 11.

PMID:
30017904
6.

Toxicology Meets Pharmacodynamics and Pharmacokinetics - New Concepts, Models and In Vitro Approaches and Tools.

Heinonen T, Pelkonen O, Tähti H.

Basic Clin Pharmacol Toxicol. 2018 Sep;123 Suppl 5:3-5. doi: 10.1111/bcpt.13080. Epub 2018 Aug 22. No abstract available.

7.

Cytochrome P450 Induction and Xeno-Sensing Receptors Pregnane X Receptor, Constitutive Androstane Receptor, Aryl Hydrocarbon Receptor and Peroxisome Proliferator-Activated Receptor α at the Crossroads of Toxicokinetics and Toxicodynamics.

Hakkola J, Bernasconi C, Coecke S, Richert L, Andersson TB, Pelkonen O.

Basic Clin Pharmacol Toxicol. 2018 Sep;123 Suppl 5:42-50. doi: 10.1111/bcpt.13004. Epub 2018 Apr 29. Review.

8.

Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research.

Pelkonen O, Terron A, Hernandez AF, Menendez P, Bennekou SH; EFSA WG EPI1 and its other members.

Arch Toxicol. 2017 Aug;91(8):2763-2780. doi: 10.1007/s00204-017-1986-x. Epub 2017 May 23. Review.

9.

Cardiac safety of ophthalmic timolol.

Mäenpää J, Pelkonen O.

Expert Opin Drug Saf. 2016 Nov;15(11):1549-1561. Epub 2016 Aug 31. Review.

PMID:
27534869
10.

Upholding science in health, safety and environmental risk assessments and regulations.

Aschner M, Autrup HN, Berry SC, Boobis AR, Cohen SM, Creppy EE, Dekant W, Doull J, Galli CL, Goodman JI, Gori GB, Greim HA, Joudrier P, Kaminski NE, Klaassen CD, Klaunig JE, Lotti M, Marquardt HW, Pelkonen O, Sipes IG, Wallace KB, Yamazaki H.

Toxicology. 2016 Sep 14;371:12-16. doi: 10.1016/j.tox.2016.09.005. Epub 2016 Sep 14.

11.

Response to “The Path Forward on Endocrine Disruptors Requires Focus”.

Autrup H, Barile F, Blaauboer BJ, Degen GH, Dekant W, Dietrich D, Domingo JL, Gori GB, Greim H, Hengstler JG, Kacew S, Marquardt H, Pelkonen O, Savolainen K, Vermeulen NP.

Toxicol Sci. 2016 Feb;149(2):273-4. No abstract available.

PMID:
27213197
12.

Tandem mass spectrometric analysis of S- and N-linked glutathione conjugates of pulegone and menthofuran and identification of P450 enzymes mediating their formation.

Lassila T, Mattila S, Turpeinen M, Pelkonen O, Tolonen A.

Rapid Commun Mass Spectrom. 2016 Apr 15;30(7):917-26. doi: 10.1002/rcm.7518.

PMID:
26969934
13.

Metabolism and metabolite profiles in vitro and in vivo of ospemifene in humans and preclinical species.

Uusitalo J, Turpeinen M, Tolonen A, Koskimies P, Lammintausta R, Pelkonen O.

Drug Metab Pers Ther. 2016 Mar;31(1):35-40. doi: 10.1515/dmpt-2015-0020.

PMID:
26581074
14.

Differentiation-Promoting Medium Additives for Hepatocyte Cultivation and Cryopreservation.

Gouliarmou V, Pelkonen O, Coecke S.

Methods Mol Biol. 2015;1250:143-59. doi: 10.1007/978-1-4939-2074-7_10. Review.

PMID:
26272140
15.

Formation of GSH-trapped reactive metabolites in human liver microsomes, S9 fraction, HepaRG-cells, and human hepatocytes.

Lassila T, Rousu T, Mattila S, Chesné C, Pelkonen O, Turpeinen M, Tolonen A.

J Pharm Biomed Anal. 2015 Nov 10;115:345-51. doi: 10.1016/j.jpba.2015.07.020. Epub 2015 Jul 26.

PMID:
26263063
16.

Drug Metabolism - From In Vitro to In Vivo, From Simple to Complex: Reflections of the BCPT Nordic Prize 2014 Awardee.

Pelkonen O.

Basic Clin Pharmacol Toxicol. 2015 Sep;117(3):147-55. doi: 10.1111/bcpt.12429. Epub 2015 Jul 7. Review.

17.

Principles of Pharmacology and Toxicology Also Govern Effects of Chemicals on the Endocrine System.

Autrup H, Barile FA, Blaauboer BJ, Degen GH, Dekant W, Dietrich D, Domingo JL, Gori GB, Greim H, Hengstler JG, Kacew S, Marquardt H, Pelkonen O, Savolainen K, Vermeulen NP.

Toxicol Sci. 2015 Jul;146(1):11-5. doi: 10.1093/toxsci/kfv082. Epub 2015 May 30.

PMID:
26026993
18.

Very low mammographic breast density predicts poorer outcome in patients with invasive breast cancer.

Masarwah A, Auvinen P, Sudah M, Rautiainen S, Sutela A, Pelkonen O, Oikari S, Kosma VM, Vanninen R.

Eur Radiol. 2015 Jul;25(7):1875-82. doi: 10.1007/s00330-015-3626-2. Epub 2015 Mar 4.

PMID:
25735512
19.

Biotransformation in vitro: An essential consideration in the quantitative in vitro-to-in vivo extrapolation (QIVIVE) of toxicity data.

Wilk-Zasadna I, Bernasconi C, Pelkonen O, Coecke S.

Toxicology. 2015 Jun 5;332:8-19. doi: 10.1016/j.tox.2014.10.006. Epub 2014 Oct 16. Review.

20.

Reactive metabolites in early drug development: predictive in vitro tools.

Pelkonen O, Pasanen M, Tolonen A, Koskinen M, Hakkola J, Abass K, Laine J, Hakkinen M, Juvonen R, Auriola S, Storvik M, Huuskonen P, Rousu T, Rahikkala M.

Curr Med Chem. 2015;22(4):538-50. Review.

PMID:
25312212
21.

Why is Research on Herbal Medicinal Products Important and How Can We Improve Its Quality?

Pelkonen O, Xu Q, Fan TP.

J Tradit Complement Med. 2014 Jan;4(1):1-7. doi: 10.4103/2225-4110.124323.

22.

Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.

Dietrich DR, Aulock SV, Marquardt H, Blaauboer B, Dekant W, Kehrer J, Hengstler J, Collier A, Gori GB, Pelkonen O, Lang F, Nijkamp FP, Stemmer K, Li A, Savolainen K, Hayes AW, Gooderham N, Harvey A, Barile FA.

Toxicon. 2013 Dec 15;76:A1-A2. doi: 10.1016/j.toxicon.2013.10.020. Epub 2013 Oct 24. No abstract available.

PMID:
24512766
23.

Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.

Dietrich DR, von Aulock S, Marquardt H, Blaauboer B, Dekant W, Kehrer J, Hengstler J, Collier A, Gori GB, Pelkonen O, Lang F, Nijkamp FP, Stemmer K, Li A, Savolainen K, Hayes AW, Gooderham N, Harvey A, Barile FA.

Toxicon. 2013 Dec 15;76:A1-A2. No abstract available.

PMID:
24409469
24.

PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA--EURL ECVAM ADME workshop.

Bessems JG, Loizou G, Krishnan K, Clewell HJ 3rd, Bernasconi C, Bois F, Coecke S, Collnot EM, Diembeck W, Farcal LR, Geraets L, Gundert-Remy U, Kramer N, Küsters G, Leite SB, Pelkonen OR, Schröder K, Testai E, Wilk-Zasadna I, Zaldívar-Comenges JM.

Regul Toxicol Pharmacol. 2014 Feb;68(1):119-39. doi: 10.1016/j.yrtph.2013.11.008. Epub 2013 Nov 26.

PMID:
24287156
25.

Human variation and CYP enzyme contribution in benfuracarb metabolism in human in vitro hepatic models.

Abass K, Reponen P, Mattila S, Rautio A, Pelkonen O.

Toxicol Lett. 2014 Jan 13;224(2):300-9. doi: 10.1016/j.toxlet.2013.08.023. Epub 2013 Sep 7.

PMID:
24016712
26.

Analytical challenges for conducting rapid metabolism characterization for QIVIVE.

Tolonen A, Pelkonen O.

Toxicology. 2015 Jun 5;332:20-9. doi: 10.1016/j.tox.2013.08.010. Epub 2013 Aug 28. Review.

PMID:
23994130
27.

Open letter to the European Commission: scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science, and risk assessment principles.

Dietrich D, von Aulock S, Marquardt HW, Blaauboer BJ, Dekant W, Kehrer J, Hengstler JG, Collier AC, Gori GB, Pelkonen O, Lang F, Nijkamp FP, Stemmer K, Li A, Savolainen K, Hayes AW, Gooderham N, Harvey A.

Arch Toxicol. 2013 Sep;87(9):1739-41. doi: 10.1007/s00204-013-1117-2. Epub 2013 Aug 27. No abstract available.

PMID:
23979651
28.

Comparative metabolism of benfuracarb in in vitro mammalian hepatic microsomes model and its implications for chemical risk assessment.

Abass K, Reponen P, Mattila S, Rautio A, Pelkonen O.

Toxicol Lett. 2014 Jan 13;224(2):290-9. doi: 10.1016/j.toxlet.2013.08.009. Epub 2013 Aug 16.

PMID:
23958702
29.

Estimation of health risk by using toxicokinetic modelling: a case study of polychlorinated biphenyl PCB153.

Abass K, Huusko A, Nieminen P, Myllynen P, Pelkonen O, Vahakangas K, Rautio A.

J Hazard Mater. 2013 Oct 15;261:1-10. doi: 10.1016/j.jhazmat.2013.07.011. Epub 2013 Jul 13.

PMID:
23911823
30.

Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo.

Turpeinen M, Uusitalo J, Lehtinen T, Kailajärvi M, Pelkonen O, Vuorinen J, Tapanainen P, Stjernschantz C, Lammintausta R, Scheinin M.

Int J Mol Sci. 2013 Jul 5;14(7):14064-75. doi: 10.3390/ijms140714064.

31.

Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.

Dietrich DR, von Aulock S, Marquardt H, Blaauboer B, Dekant W, Kehrer J, Hengstler J, Collier A, Batta Gori G, Pelkonen O, Lang F, Nijkamp FP, Stemmer K, Li A, Savolainen K, Wallace Hayes A, Gooderham N, Harvey A.

ALTEX. 2013;30(3):381-5. doi: 10.14573/altex.2013.3.381. No abstract available.

32.

Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene.

Lehtinen T, Tolonen A, Turpeinen M, Uusitalo J, Vuorinen J, Lammintausta R, Pelkonen O, Scheinin M.

Biopharm Drug Dispos. 2013 Oct;34(7):387-95. doi: 10.1002/bdd.1853. Epub 2013 Aug 15.

PMID:
23852652
33.

Editorial.

Dietrich DR, von Aulock S, Marquardt H, Blaauboer B, Dekant W, Hengstler J, Collier A, Gori GB, Pelkonen O, Lang F, Nijkamp FP, Stemmer K, Li A, Savolainen K, Hayes AW, Gooderham N, Harvey A.

Regul Toxicol Pharmacol. 2013 Dec;67(3):317-20. doi: 10.1016/j.yrtph.2013.07.001. Epub 2013 Jul 9. No abstract available.

PMID:
23850959
34.

Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.

Dietrich DR, von Aulock S, Marquardt H, Blaauboer B, Dekant W, Kehrer J, Hengstler J, Collier A, Gori GB, Pelkonen OP, Lang F, Nijkamp FP, Stemmer K, Li A, Savolainen K, Hayes A, Gooderham N, Harvey A.

Toxicol In Vitro. 2013 Oct;27(7):2110-4. doi: 10.1016/j.tiv.2013.07.001. Epub 2013 Jul 9. No abstract available.

PMID:
23850741
35.

Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.

Dietrich DR, von Aulock S, Marquardt H, Blaauboer B, Dekant W, Kehrer J, Hengstler J, Collier A, Gori GB, Pelkonen O, Lang F, Nijkamp FP, Stemmer K, Li A, Savolainen K, Hayes AW, Gooderham N, Harvey A.

Food Chem Toxicol. 2013 Dec;62:A1-4. doi: 10.1016/j.fct.2013.07.005. Epub 2013 Jul 5. No abstract available.

PMID:
23835284
36.

Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.

Dietrich DR, Aulock Sv, Marquardt H, Blaauboer B, Dekant W, Kehrer J, Hengstler J, Collier A, Gori GB, Pelkonen O, Lang F, Barile FA, Nijkamp FP, Stemmer K, Li A, Savolainen K, Hayes AW, Gooderham N, Harvey A.

Chem Biol Interact. 2013 Sep 5;205(1):A1-5. doi: 10.1016/j.cbi.2013.07.001. Epub 2013 Jul 4. No abstract available.

PMID:
23832050
37.

Axillary lymph node biopsy in newly diagnosed invasive breast cancer: comparative accuracy of fine-needle aspiration biopsy versus core-needle biopsy.

Rautiainen S, Masarwah A, Sudah M, Sutela A, Pelkonen O, Joukainen S, Sironen R, Kärjä V, Vanninen R.

Radiology. 2013 Oct;269(1):54-60. doi: 10.1148/radiol.13122637. Epub 2013 Jun 14.

PMID:
23771915
38.

Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations.

Tolonen A, Koskimies P, Turpeinen M, Uusitalo J, Lammintausta R, Pelkonen O.

Drug Metabol Drug Interact. 2013;28(3):153-61. doi: 10.1515/dmdi-2013-0016.

PMID:
23729558
39.

Thujone and thujone-containing herbal medicinal and botanical products: toxicological assessment.

Pelkonen O, Abass K, Wiesner J.

Regul Toxicol Pharmacol. 2013 Feb;65(1):100-7. doi: 10.1016/j.yrtph.2012.11.002. Epub 2012 Nov 28. Review.

PMID:
23201408
40.

Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches.

Coecke S, Pelkonen O, Leite SB, Bernauer U, Bessems JG, Bois FY, Gundert-Remy U, Loizou G, Testai E, Zaldívar JM.

Toxicol In Vitro. 2013 Aug;27(5):1570-7. doi: 10.1016/j.tiv.2012.06.012. Epub 2012 Jul 4. Review.

PMID:
22771339
41.

Preservation, induction or incorporation of metabolism into the in vitro cellular system - views to current opportunities and limitations.

Pelkonen O, Turpeinen M, Hakkola J, Abass K, Pasanen M, Raunio H, Vähäkangas K.

Toxicol In Vitro. 2013 Aug;27(5):1578-83. doi: 10.1016/j.tiv.2012.06.002. Epub 2012 Jun 19.

PMID:
22728233
42.

The inhibition of major human hepatic cytochrome P450 enzymes by 18 pesticides: comparison of the N-in-one and single substrate approaches.

Abass K, Pelkonen O.

Toxicol In Vitro. 2013 Aug;27(5):1584-8. doi: 10.1016/j.tiv.2012.05.003. Epub 2012 May 23.

PMID:
22634058
43.

Review of current and "omics" methods for assessing the toxicity (genotoxicity, teratogenicity and nephrotoxicity) of herbal medicines and mushrooms.

Ouedraogo M, Baudoux T, Stévigny C, Nortier J, Colet JM, Efferth T, Qu F, Zhou J, Chan K, Shaw D, Pelkonen O, Duez P.

J Ethnopharmacol. 2012 Apr 10;140(3):492-512. doi: 10.1016/j.jep.2012.01.059. Epub 2012 Feb 22. Review.

44.

Omics and its potential impact on R&D and regulation of complex herbal products.

Pelkonen O, Pasanen M, Lindon JC, Chan K, Zhao L, Deal G, Xu Q, Fan TP.

J Ethnopharmacol. 2012 Apr 10;140(3):587-93. doi: 10.1016/j.jep.2012.01.035. Epub 2012 Feb 1. Review.

45.

Characterization of human cytochrome P450 induction by pesticides.

Abass K, Lämsä V, Reponen P, Küblbeck J, Honkakoski P, Mattila S, Pelkonen O, Hakkola J.

Toxicology. 2012 Mar 29;294(1):17-26. doi: 10.1016/j.tox.2012.01.010. Epub 2012 Jan 28.

PMID:
22310298
46.

A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing.

Basketter DA, Clewell H, Kimber I, Rossi A, Blaauboer B, Burrier R, Daneshian M, Eskes C, Goldberg A, Hasiwa N, Hoffmann S, Jaworska J, Knudsen TB, Landsiedel R, Leist M, Locke P, Maxwell G, McKim J, McVey EA, Ouédraogo G, Patlewicz G, Pelkonen O, Roggen E, Rovida C, Ruhdel I, Schwarz M, Schepky A, Schoeters G, Skinner N, Trentz K, Turner M, Vanparys P, Yager J, Zurlo J, Hartung T.

ALTEX. 2012;29(1):3-91. doi: 10.14573/altex.2012.1.003.

PMID:
22307314
47.

Significant interspecies differences in induction profiles of hepatic CYP enzymes by TCDD in bank and field voles.

Murtomaa-Hautala M, Korkalainen M, Pelkonen O, Hegde N, Pohjanvirta R, Huitu O, Henttonen H, Rautio A, Viitala P, Viluksela M.

Environ Toxicol Chem. 2012 Mar;31(3):663-71. doi: 10.1002/etc.1737. Epub 2012 Feb 6.

PMID:
22213473
48.

Hepatocytes: the powerhouse of biotransformation.

Sevior DK, Pelkonen O, Ahokas JT.

Int J Biochem Cell Biol. 2012 Feb;44(2):257-61. doi: 10.1016/j.biocel.2011.11.011. Epub 2011 Nov 20. Review.

PMID:
22123318
49.

In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions.

Pelkonen O, Turpeinen M, Raunio H.

Clin Pharmacokinet. 2011 Aug;50(8):483-91. doi: 10.2165/11592400-000000000-00000.

PMID:
21740072
50.

Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010.

Adler S, Basketter D, Creton S, Pelkonen O, van Benthem J, Zuang V, Andersen KE, Angers-Loustau A, Aptula A, Bal-Price A, Benfenati E, Bernauer U, Bessems J, Bois FY, Boobis A, Brandon E, Bremer S, Broschard T, Casati S, Coecke S, Corvi R, Cronin M, Daston G, Dekant W, Felter S, Grignard E, Gundert-Remy U, Heinonen T, Kimber I, Kleinjans J, Komulainen H, Kreiling R, Kreysa J, Leite SB, Loizou G, Maxwell G, Mazzatorta P, Munn S, Pfuhler S, Phrakonkham P, Piersma A, Poth A, Prieto P, Repetto G, Rogiers V, Schoeters G, Schwarz M, Serafimova R, Tähti H, Testai E, van Delft J, van Loveren H, Vinken M, Worth A, Zaldivar JM.

Arch Toxicol. 2011 May;85(5):367-485. doi: 10.1007/s00204-011-0693-2. Epub 2011 May 1. Review.

PMID:
21533817

Supplemental Content

Loading ...
Support Center